Results 71 to 80 of about 19,727 (209)

Chronic hepatitis in horses with persistent equine hepacivirus infection

Equine Veterinary Journal, Volume 58, Issue 2, Page 444-457, March 2026.
Abstract Background Equine hepacivirus (EqHV) is closely related to hepatitis C virus (HCV), which causes persistent infection and chronic hepatitis in people. Information on persistent EqHV infection and hepatitis is limited. Objectives To report 19 cases of chronic hepatitis and persistent EqHV infection.
Mason C. Jager, Daniela Luethy, Samantha Shallop, Jessica Cathcart, Thomas J. Divers, Jean‐Yin Tan, Erin McConachie Beasley, Philip Johnson, Laurence Leduc, Claire Smith, Camilla Anne Jamieson, K. Gary Magdesian, Gerlinde R. Van de Walle, Joy E. Tomlinson   +13 more
wiley   +1 more source

Molecular docking and statistical optimization of taurocholate-stabilized galactose anchored bilosomes for the enhancement of sofosbuvir absorption and hepatic relative targeting efficiency

Drug Delivery, 2020
The work aimed to improve both absorption and hepatic availability of sofosbuvir. Bilosomes and galactose-anchored bilosomes were investigated as potential nanocarriers for this purpose.
Marianne Joseph Naguib, Amira Moustafa Kamel, Ahmed Thabet Negmeldin, Ahmed Hassen Elshafeey, Ibrahim Elsayed   +4 more
doaj   +1 more source

Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis

, 2014
AIM: To investigate the predictability of interleukin-28B single nucleotide polymorphism rs12979860 with respect to sustained virological response (SVR) in chronically hepatitis C virus (HCV) genotype-1 patients treated with a protease-inhibitor and ...
Amanzada, Ahmad, Cameron, Silke, Mechie, Nicolae-Catalin, Röver, Christian   +3 more
core   +1 more source

Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

Infection and Drug Resistance, 2019
Lindsey M Childs-Kean, Natalie A Brumwell, Emma F LodlDepartment of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL, USAAbstract: The treatment of chronic hepatitis C has been revolutionized with the
Childs-Kean LM, Brumwell NA, Lodl EF
doaj  

Sofosbuvir and daclatasvir [PDF]

British Journal of Clinical Pharmacology, 2016
Chronic hepatitis C infection is a major cause of chronic liver disease, cirrhosis and liver cancer as well as an important indication for liver transplantation. Sofosbuvir (Sovaldi®) 1 and daclatasvir (Daklinza®) 2 are new direct acting antivirals (DAAs) with a favourable safety and tolerability profile, which have significantly changed treatment for ...
Marleen H. M. Hessel, Adam F. Cohen, Robert Rissmann   +2 more
openaire   +2 more sources

Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C. [PDF]

, 2017
Background and Aims: Recurrent infection of hepatitis C virus (HCV) in liver transplant (LT) recipients is universal and associated with significant morbidity and mortality.
Bau, Sherona N, Busuttil, Ronald W, Choi, Gina, Durazo, Francisco A, El-Kabany, Mohammed M, Esmailzadeh, Negin L, Fong, Tiffany M, Grotts, Jonathan, Han, Steven-Huy B, Jimenez, Melissa A, Kachadoorian, Caterina A, Kang, Susan, Mai, Michelle H, Ramirez, Samantha D, Rheem, Justin, Saab, Sammy   +15 more
core   +1 more source

Unveiling the Crucial Nexus: Mitochondrial Quality Control as a Central Driver in Metabolic Dysfunction‐Associated Steatotic Liver Disease Pathogenesis

Cell Proliferation, Volume 59, Issue 2, February 2026.
Mitochondrial quality control (MQC) impairment plays a central role in driving the pathogenesis of metabolism‐associated steatotic liver disease (MASLD). Specifically, this is manifested as reduced mitophagy; increased mitochondrial fission and decreased fusion; and impaired mitochondrial biogenesis.
Wenkai Fu, Junqi Wang, Nan Lu, Zhijiang Guo, Sang‐Bing Ong, Yong Gao, Hao Zhou, Xing Chang, Miao Meng   +8 more
wiley   +1 more source

EVALUATION OF EFFECTIVENESS OF ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C, CAUSED BY HCV GENOTYPE 6

Журнал инфектологии, 2017
Objectives: Evaluating the effectiveness of 2 therapeutic schemes for chronic hepatitis C (genotype 6) which combined sofosbuvir and ribavirin, one of them also included pegylated interferon.
D. A. Lioznov, N. H. Chung, S. L. Nikolaenko, T. B. Trung, F. T. Lan, N. D. Phong   +5 more
doaj   +1 more source

Treatment of chronic hepatitis C with sofosbuvir in a hemodialysis patient: a case report

The Pan African Medical Journal, 2021
The treatment of chronic hepatitis C virus (HCV) infection in chronic hemodialysis patients remains an issue of great concern for nephrologists. In 2008 the kidney disease improving global outcomes working group suggested the use of pegylated interferon ...
Marius Tchoupe Djoumbissie, Hanen Chaker, Mona Boudabbous, Salma Toumi, François Pegdebamba Kissou, Saba Gargouri, Khawla Kammoun, Faiçal Jarraya, Nabil Tahri, Soumaya Yaich, Mohamed Ben Hmida   +10 more
doaj   +1 more source

Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection. [PDF]

, 2020
Currently, the only approved hepatitis C virus (HCV) treatment for children aged <12 years is pegylated interferon plus ribavirin. In an open-label study, we evaluated the safety and efficacy of sofosbuvir plus ribavirin for 12 weeks in children aged ...
Balistreri, William F, Bansal, Sanjay, Brainard, Diana M, Davison, Suzanne, Feiterna-Sperling, Cornelia, Gillis, Lynette A, Gonzalez-Peralta, Regino P, Hsueh, Chia-Hsiang, Indolfi, Giuseppe, Jonas, Maureen M, Kelly, Deidre A, Lin, Chuan-Hao, Massetto, Benedetta, Murray, Karen F, Nightingale, Scott, Parhy, Bandita, Rosenthal, Philip, Schwarz, Kathleen B, Shao, Jiang, Sokal, Etienne M, Wirth, Stefan   +20 more
core